RH

Reza Halse

Partner at Droia Ventures

West Newton, Massachusetts

Overview 

Reza Halse is a Partner at Droia Ventures, with a background in cell biology, genomics, and biotechnology. He has held significant leadership roles at Merck, RA Capital Management, and MSD, and has been involved in the success of various companies through his board responsibilities and investments in therapeutics and biotech sectors. Highlights of Reza Halse's career include serving as the Head of Pacific BD&L Hub at Merck and being a Partner at RA Capital Management, showcasing his expertise in venture capital, drug discovery, and commercialization within the pharmaceutical industry. Additionally, his current role as a Partner at Droia Ventures allows him to leverage his extensive experience in technology transfer and clinical development to support companies in their growth and development.

Work Experience 

DV

Droia Ventures

  • Partner

    2023 - Current

RC

RA Capital Management, L.P.

  • Partner, RA Ventures

    2021 - 2023

RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.

racap.com
M

Merck

  • Head, Pacific BD&L Hub (Vice President)

    2019 - 2021

  • President, MRL Ventures Fund

    2017 - 2021

Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.

Raised $5,586,000.00 from Private Capital Advisors.

merck.com

Caraway, LifeMine, Lava, Editas, Imago, Adheron, Spero, Alector, LTI, RaNA, miRagen, Visterra

  • Previous Board responsibilities

    2012 - 2021

M

MSD

  • Associate Vice President and Head of MSD European Innovation Hub; Partner, MRL Venture Fund

    2015 - 2016

    Rez leads the MSD London Innovation Hub with responsibility for business development and licensing activities in Europe; he is also a Partner in MRL Ventures. Recognizing the importance of life-science innovation in Europe, MSD has established the London Innovation Hub as a focal point for developing academic and commercial partnerships. The Hub offers a range of partnering constructs to match the interests of European innovators: collaborations, licensing and independent venture investments, through MRL Ventures.

GC

Genome Canada

  • Chair, Core Evaluation Team, Genomic Applications Partnership Program

    2013 - 2016

Partners HealthCare

  • Partner, Innovation Fund

    2012 - 2015

Targanox

  • CEO

    2014 - 2015

BioMed Valley Discoveries

  • Director

    2008 - 2011

NI

Novartis Institutes for BioMedical Research

  • Associate Director

    2004 - 2008

Education 

Investments 

ADCendo

Series A

Total funding: $110M

Caraway Therapeutics

Series A

Total funding: $46M

Spero Therapeutics

Seed

Total funding: $120M

Raze Therapeutics

Series A

Total funding: $24M

Articles About Reza

Relevant Websites